细胞因子受体3对膀胱尿路上皮癌患者接受吉西他滨化疗的敏感性和预后预测价值  

The Predictive Value of Cytokine Receptor 3 on the Sensitivity to Gemcitabine Chemotherapy and Prognosis in Patients with Bladder Urothelial Carcinoma

作　　者：岳霄[1] 王强 刘良 YUE Xiao;WANG Qiang;LIU Liang(Department of Urology,Baoding First Central Hospital,Baoding,Hebei 071000,China)

机构地区：[1]保定市第一中心医院泌尿一科,河北保定071000

出　　处：《转化医学杂志》2024年第11期1862-1865,共4页Translational Medicine Journal

基　　金：2023年河北省卫生健康委员会科学研究课题项目(20241833)。

摘　　要：目的探讨细胞因子受体3(CXCR3)在膀胱尿路上皮癌患者接受吉西他滨化疗中的敏感性和预后预测价值。方法回顾性分析2022年1月至2024年1月保定市第一中心医院收治的120例膀胱尿路上皮癌患者,收集患者的临床资料,依据实体肿瘤疗效评价标准RECIST1.1分为敏感组和耐药组,检测2组CXCR3水平,使用Logistic回归分析化疗敏感性的影响因素,受试者工作特征曲线(ROC)评估CXCR3水平对预后的预测价值。结果在120例患者中,敏感组77例,耐药组43例。敏感组与耐药组在年龄、BMI、性别上差异无统计学意义(P>0.05),而在吸烟史、病理学分级上差异有统计学意义(P<0.05)。敏感组的CXCR3表达水平高于耐药组(P<0.05)。敏感组的预后不良发生率低于耐药组(P<0.05)。Logistic回归分析表明,病理学分级、吸烟史和CXCR3水平是影响化疗敏感性的独立影响因素。ROC曲线分析显示,CXCR3预测患者预后不良的AUC为0.887,具有良好的预测价值。结论CXCR3的表达水平可以作为膀胱尿路上皮癌患者接受吉西他滨化疗敏感性和预后的预测指标,具有潜在的临床应用价值。Objective To investigate the sensitivity and prognostic predictive value of C-X-C chemokine receptor type 3(CXCR3)in patients with bladder urothelial carcinoma undergoing gemcitabine chemotherapy.Methods A retrospective analysis was conducted on 120 patients with bladder urothelial carcinoma admitted between January 2022 and January 2024.Clinical data of the patients were collected,and based on the RECIST 1.1 criteria for solid tumor response,patients were divided into the sensitive group and the resistant group.CXCR3 levels were measured in both groups.Logistic regression was used to analyze the factors influencing chemotherapy sensitivity,and the predictive value of CXCR3 for prognosis was assessed using the ROC curve.Results Out of the 120 patients,77 were in the sensitive group and 43 were in the resistant group.There were no significant differences between the two groups in terms of age,BMI,or gender(P>0.05),but significant differences were found in smoking history and pathological grading(P<0.05).CXCR3 expression levels were higher in the sensitive group than in the resistant group(P<0.05).The incidence of poor prognosis was lower in the sensitive group compared to the resistant group(P<0.05).Logistic regression analysis indicated that pathological grading,smoking history,and CXCR3 levels were independent factors affecting chemotherapy sensitivity.ROC curve analysis showed that the AUC for CXCR3 predicting poor prognosis was 0.887,demonstrating good predictive value.Conclusion The expression level of CXCR3 can serve as a predictive marker for sensitivity to gemcitabine chemotherapy and prognosis in patients with bladder urothelial carcinoma,with potential clinical application value.

关 键 词：膀胱尿路上皮癌 CXCR3 吉西他滨 化疗敏感性 预后预测 

分 类 号：R699[医药卫生—泌尿科学]